Second-line chemotherapy for non-small cell lung cancer

Chest

Volumn 129, Issue 4, 2006, Pages 840-842

  Ruckdeschel, John C ^a,b  

^a Karmanos Cancer Institute ^*  (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DRUG CHOICE; EDITORIAL; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33646002064     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.4.840     Document Type: Editorial

References (16)

1. Chen Y-M, Shih, J-F, Perng R-P, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who have failed prior platinum-based chemotherapy. Chest 2006; 129:1031-1038
2. Simon R. Designs for efficient clinical trials. Oncology 1989; 3:43-49
3. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69:1375-1381
4. Schuette W, Nagel S, Blankenburg T, et al. Phase III study of second-line chemotherapy for advanced non-small cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005; 23:8389-8395
5. Hanna N. Advances in the treatment of second-line non-small cell lung cancer. Lung Cancer 2005; 50(Suppl 1):S15-S17
6. Cappuzzo F, Finocchiaro G, Trisolini R, et al. Perspectives on salvage therapy for non-small cell lung cancer. Oncology 2005; 19:989-995
7. Bonomi P. Therapeutic advances in second-line treatment of advanced non-small cell lung cancer. Clin Lung Cancer 2004; 6:154-161
8. Ruckdeschel JC, Finkelsetin DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986; 4:14-20
9. Soscinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123(Suppl):226S-243S
10. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346:92
11. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 2005; 10:3235-3242
12. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC#704865) in patients with advanced non-squamous non-small cell lung cancer: an Eastern Cooperative Oncology Group Trial- E4599. Proc Am Soc Clin Oncol 2005; 23:1090s
13. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597
14. Mukohara T, Takeda K, Miyazaki M, et al. Japanese experience with second-line chemotherapy with low-dose (60mg/M2) docetaxel in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2001; 48:356-360
15. Gandara DR, Ohe Y, Kubota K, et al. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): a model for prospective comparison of cooperative group trials. Proc Am Soc Clin Oncol 2004; 22:a7007
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139